Finerenone in Primary IgA Nephropathy: A Matched Case-Control Study.

Kidney Dis (Basel) · 2025 · PMC12215197 · PMID 40606678

Europe PMC DOI

hedged sentence

0.2900

closest p · 5.8× alpha

0.2900

boldest claim

The sentences

did not reach statistical significancep = 0.29not close (p > 0.1)

For the renal composite endpoint, the risk ratio was 0.80 (95% CI: 0.69–0.92) without SGLT2i use and 0.42 (95% CI: 0.16–1.08) with SGLT2i use, suggesting that SGLT2i treatment may further potentiate the effect of finerenone in reducing the risk of renal events, although this difference did not reach statistical significance (interaction p = 0.29).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.